Obstructive sleep apnea (OSA) is a common sleep disorder that affects nearly one billion people worldwide. It’s more than just disrupted sleep; OSA is associated with serious health problems, including heart disease, brain disorders, and metabolic issues.
Despite the widespread use of continuous positive airway pressure (CPAP) devices to manage the condition, these treatments don’t fully address the long-term health effects caused by OSA.
A new study published in the American Journal of Respiratory and Critical Care Medicine offers hope for improving treatment.
Researchers, including experts from the University of Missouri School of Medicine, explored the use of senolytics—drugs designed to target and remove aging cells—as an additional therapy for OSA. These aging cells, known as senescent cells, are linked to accelerated aging and chronic health issues.
The research team, led by Dr. Gozal, investigated a combination treatment approach using senolytic drugs alongside a simulated version of CPAP adherence. The experiments were conducted on mice exposed to intermittent low oxygen levels, a condition similar to what OSA patients experience during sleep.
The findings were remarkable. When the mice were treated with both partial normoxic recovery (mimicking proper CPAP use) and a senolytic drug called Navitoclax (NAV), they showed significant improvements in several areas.
These included better cognitive function, reduced sleepiness during their natural rest period, improved heart artery health, better metabolism, and even reduced gut permeability—an indicator of improved overall health.
Interestingly, these benefits were not seen with CPAP treatment alone. This suggests that while CPAP helps normalize breathing, it does not address the deeper cellular damage and accelerated aging caused by OSA. By targeting these aging processes, senolytics may offer a way to reverse some of the broader health effects of the condition.
Dr. Mohammad Badran, a co-author of the study, highlighted that traditional treatments like CPAP fail to fully address the damage OSA causes to major organs. Adding senolytics to the treatment plan could be a key step in managing these issues more effectively.
This combined therapy approach also underscores the potential for improving heart health, metabolism, and even gut function in OSA patients, offering a more comprehensive solution to the condition. The findings pave the way for future clinical trials to determine if these promising results can be replicated in human patients.
The study represents a significant advancement in sleep medicine and highlights the importance of looking beyond just treating symptoms. By addressing the underlying aging processes caused by OSA, this research could lead to innovative therapies that improve the overall health and quality of life for millions of people.
While further studies are needed to develop safe and effective senolytic treatments for OSA, this research offers new hope for those living with the condition and its related health challenges. For now, it serves as a reminder of the importance of advancing medical science to find more holistic solutions for complex disorders like sleep apnea.
You can find more details about the study in the American Journal of Respiratory and Critical Care Medicine.
If you care about sleep, please read studies about herb that could help you sleep well at night, and these drugs could lower severity of sleep apnea by one third.
For more health information, please see recent studies that coffee boosts your physical activity, cuts sleep, affects heartbeat, and results showing how to deal with “COVID-somnia” and sleep well at night.
Copyright © 2025 Knowridge Science Report. All rights reserved.
